Drug Type Small molecule drug |
Synonyms A400, EP-0031, EP0031 + [1] |
Target |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US), Fast Track (US) |
Molecular FormulaC28H28FN11 |
InChIKeySYAIWXURFWCECS-UHFFFAOYSA-N |
CAS Registry2479961-46-9 |
Start Date18 Mar 2024 |
Sponsor / Collaborator |
Start Date29 Aug 2023 |
Sponsor / Collaborator |
Start Date21 Aug 2023 |
Sponsor / Collaborator- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Jun 2021 | |
RET Mutation-Positive Medullary Thyroid Cancer | IND Approval | CN | 24 Jul 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 27 | fltklrbids(euatiqmyum) = No DLTs were observed lxackbsnwb (xnpgbyoctm ) View more | Positive | 24 May 2024 | |||
Phase 1 | RET mutation Solid Tumors RET Fusion | 87 | oevqetksyr(atxxietvia) = Not reached xotemxgfeg (bgiylbxizf ) View more | Positive | 31 May 2023 |